Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
The stage at which your multiple myeloma (MM) is diagnosed will often dictate your multiple myeloma therapy plan. Stage 1 MM is treated differently than stage 3 MM. Research and personal experience has taught me that multiple myeloma patients and survivors must use the best of both conventional (FDA) therapies as well as the best of non-conventional MM therapies. CBD aka cannabinoids are an evidence-based, non-conventional multiple myeloma therapy.
While there is a long and growing list of FDA approved chemotherapy regimens for MM such as Velcade and Carfilzomib (kyprolis), there are evidence-based, “integrative therapies” for MM that have been shown to enhance the efficacy of chemo while reducing the risk of side effects.
Cannabidiol or CBD is an integrative multiple myeloma therapy.
Cannabidiol is one of many evidence-based, non-conventional MM therapies shown to be cytotoxic to MM, and shown to integrate with MM chemotherapies such as Velcade, Revlimid, Cytoxan, Melphalan and Dexamethasone.
There are a host of evidence-based, non-toxic MM therapies for you to consider.
“These results showed that CBD by itself or in synergy with BORT strongly inhibited growth, arrested cell cycle progression and induced MM cells death by regulating the ERK, AKT and NF-κB pathways with major effects in TRPV2+ cells. These data provide a rationale for using CBD to increase the activity of proteasome inhibitors in MM.”
“Cannabidiol, a non-psychotropic component of marijuana, may enhance the healing process of bone fissures, according to a new study…
We found that CBD alone makes bones stronger during healing, enhancing the maturation of the collagenous matrix, which provides the basis for new mineralization of bone tissue. After being treated with CBD, the healed bone will be harder to break in the future.“”
“Cannabinoids may offer significant “side benefits” beyond analgesia. These include anti-emetic effects, well established with THC, but additionally demonstrated for CBD (Pertwee 2005), the ability of THC and CBD to produce apoptosis in malignant cells and inhibit cancer-induced angiogenesis (Kogan 2005; Ligresti et al 2006), as well as the neuroprotective antioxidant properties of the two substances (Hampson et al 1998), and improvements in symptomatic insomnia (Russo et al 2007)…”
…we also found that the CBD and THC combination is able to reduce expression of the β5i subunit as well as to act in synergy with Carfilzomib (CFZ) to increase MM cell death…
A myeloma diagnosis results in induction therapy (perhaps RVd), MM remission, an autologous stem cell transplant, and another, hopefully, deeper MM remission. While research has never confirmed that ASCT provides a longer overall survival (OS), research does demonstrate that the average PFS or remission is longer with an ASCT.
But now you are coming out of remission…does this mean that you are running out of therapy options? Am I nearer to the end than the beginning? Conventional wisdom says that your next remission will be shorter than your first. Just as important, you have suffered several short, long-term and late stage side effects. You are tired of the side effects that come from chemotherapy.
So what’s a relapsed/refractory MMer to do? Your oncologist is suggesting carfilzomib but you’ve heard about the difficult toxicity and side effects of this chemotherapy regimen.
According to the two studies linked and excerpted below, CBD and curcumin act synergistically to both enhance the MM killing action of CFZ as well as reduce the toxicity of CFZ. But maybe you are wondering if either/or of these integrative therapies can interfere with the efficacy of carfilzomib.
To quote “this combination (CBD and CFZ) exerts strong anti-MM activities” and “curcumin can ameliorate carfilzomib efficacy…”
To be fair, the studies below are “in vitro” meaning they take place in a test tube. No pharmaceutical company in existance is going to test a unpatentable product like curcumin or CBD in human beings. To a large extent, myeloma patients and survivors are on their own in the latter stages of their incurable disease.
“Herein, we also found that the CBD and THC combination is able to reduce expression of the β5i subunit as well as to act in synergy with Carfilzomib (CFZ) to increase MM cell death and inhibits cell migration. In summary, these results proved that this combination exerts strong anti-myeloma activities…
In multiple myeloma, our previous findings demonstrated that CBD reduced cell proliferation and induced necrotic cell death . In the present study, our data on THC and mainly on the THC-CBD combination as stimulatory factors of autophagic-dependent cell death in MM cell lines, support previous data regarding the efficacy of cannabinoids as anti-tumoral drugs, in different human cancer models.
For cannabinoids, different experimental data suggested that the combined administration of cannabinoids with other anti-cancer drugs, could act synergistically, to reduce tumor growth and chemoresistance...
In MM cells, the CBD and Bortezomib (BTZ) combination was found to be more effective compared with BTZ alone and to act synergistically in inducing cell death .
Herein we investigated the effect of CBD and THC in combination with CFZ, showing a synergistic effect between the three drugs, supporting the fact that combining THC-CBD with established cytotoxic agents should result in a higher level of anticancer activity compared with that of cytotoxic agents acting alone…
Therefore, a combination therapy including cannabinoids and chemotherapeutic drugs could allow the reduction of chemotherapeutical doses administered in patients, without affecting the antitumoral therapy...
“Multiple myeloma (MM) is a malignant B-cell neoplasm with accumulation of malignant plasma cells in bone marrow. Pharmacological therapy improves response frequency even if with various associated toxicities.
Herein, we investigated if combination of curcumin with carfilzomib (CFZ) can induce a better cytotoxic effect on in vitro cultured U266 cells. Cell viability data showed that curcumin significantly ameliorates CFZ cytotoxic effect.
Furthermore, curcumin alone did not affect proteasome at the tested dose, confirming the involvement of different mechanisms in the observed effects. U266 cells exposure to curcumin or carfilzomib (CFZ) increased reactive species (RS) levels, although their production did not appear further potentiated following drugs combination.
Interestingly, NF-κB nuclear accumulation was reduced by treatment with CFZ or curcumin, and was more deeply decreased in cells treated with CFZ-curcumin combinations, very likely due to the different mechanisms through which they target NF-κB.
Our results confirmed the induction of p53/p21 axis and G0/G1 cell cycle arrest in anticancer activities of both drugs, an effect more pronounced for the CFZ-curcumin tested combinations.
Furthermore, curcumin addition enhanced CFZ proapoptotic effect.
These findings evidence that curcumin can ameliorate CFZ efficacy, and lead us to hypothesize that this effect might be useful to optimize CFZ therapy in MM patients.”